Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. more
Time Frame | CGEN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.4% | -0.94% | -2.6% |
1-Month Return | 7.8% | -5.08% | -1.08% |
3-Month Return | -13.64% | -10.62% | 3.45% |
6-Month Return | -18.72% | -6.18% | 8.57% |
1-Year Return | -11.63% | 1.98% | 24.3% |
3-Year Return | -66.67% | -0.93% | 25.58% |
5-Year Return | -73.79% | 33.84% | 84.07% |
10-Year Return | -82.63% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 2.00M | 6.00M | 7.50M | 33.46M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":5.98,"profit":true},{"date":"2021-12-31","value":17.93,"profit":true},{"date":"2022-12-31","value":22.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 989.00K | 60.00K | 680.00K | 975.00K | 2.00M | [{"date":"2019-12-31","value":49.35,"profit":true},{"date":"2020-12-31","value":2.99,"profit":true},{"date":"2021-12-31","value":33.93,"profit":true},{"date":"2022-12-31","value":48.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (989.00K) | 1.94M | 5.32M | 6.53M | 31.45M | [{"date":"2019-12-31","value":-3.14,"profit":false},{"date":"2020-12-31","value":6.17,"profit":true},{"date":"2021-12-31","value":16.91,"profit":true},{"date":"2022-12-31","value":20.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | 97.00% | 88.67% | 87.00% | 94.01% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.41,"profit":true},{"date":"2022-12-31","value":89.69,"profit":true},{"date":"2023-12-31","value":96.92,"profit":true}] |
Operating Expenses | 28.88M | 33.44M | 40.39M | 41.90M | 44.45M | [{"date":"2019-12-31","value":64.97,"profit":true},{"date":"2020-12-31","value":75.23,"profit":true},{"date":"2021-12-31","value":90.88,"profit":true},{"date":"2022-12-31","value":94.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (28.88M) | (31.50M) | (35.07M) | (35.37M) | (12.99M) | [{"date":"2019-12-31","value":-2887900000,"profit":false},{"date":"2020-12-31","value":-3149600000,"profit":false},{"date":"2021-12-31","value":-3507400000,"profit":false},{"date":"2022-12-31","value":-3537400000,"profit":false},{"date":"2023-12-31","value":-1299200000,"profit":false}] |
Total Non-Operating Income/Expense | 1.72M | 3.52M | 1.74M | 3.48M | 6.42M | [{"date":"2019-12-31","value":26.85,"profit":true},{"date":"2020-12-31","value":54.86,"profit":true},{"date":"2021-12-31","value":27.14,"profit":true},{"date":"2022-12-31","value":54.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (28.06M) | (29.70M) | (34.20M) | (33.64M) | (9.78M) | [{"date":"2019-12-31","value":-2805900000,"profit":false},{"date":"2020-12-31","value":-2969800000,"profit":false},{"date":"2021-12-31","value":-3420300000,"profit":false},{"date":"2022-12-31","value":-3363600000,"profit":false},{"date":"2023-12-31","value":-978400000,"profit":false}] |
Income Taxes | (722.00K) | (2.44M) | (1.33M) | 58.00K | 8.97M | [{"date":"2019-12-31","value":-8.05,"profit":false},{"date":"2020-12-31","value":-27.18,"profit":false},{"date":"2021-12-31","value":-14.83,"profit":false},{"date":"2022-12-31","value":0.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (27.34M) | (27.26M) | (32.87M) | (33.69M) | (18.75M) | [{"date":"2019-12-31","value":-2733700000,"profit":false},{"date":"2020-12-31","value":-2726000000,"profit":false},{"date":"2021-12-31","value":-3287300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false}] |
Income From Continuous Operations | (27.34M) | (29.70M) | (34.20M) | (33.69M) | (18.75M) | [{"date":"2019-12-31","value":-2733700000,"profit":false},{"date":"2020-12-31","value":-2969800000,"profit":false},{"date":"2021-12-31","value":-3420300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (27.34M) | (27.26M) | (32.87M) | (33.69M) | (18.75M) | [{"date":"2019-12-31","value":-2733700000,"profit":false},{"date":"2020-12-31","value":-2726000000,"profit":false},{"date":"2021-12-31","value":-3287300000,"profit":false},{"date":"2022-12-31","value":-3369400000,"profit":false},{"date":"2023-12-31","value":-1875400000,"profit":false}] |
EPS (Diluted) | (0.44) | (0.37) | (0.40) | (0.40) | (0.22) | [{"date":"2019-12-31","value":-44,"profit":false},{"date":"2020-12-31","value":-37,"profit":false},{"date":"2021-12-31","value":-40,"profit":false},{"date":"2022-12-31","value":-40,"profit":false},{"date":"2023-12-31","value":-22,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CGEN | |
---|---|
Cash Ratio | 4.06 |
Current Ratio | 4.14 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CGEN | |
---|---|
ROA (LTM) | -3.04% |
ROE (LTM) | -15.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CGEN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.51 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.49 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CGEN | |
---|---|
Trailing PE | 50.67 |
Forward PE | NM |
P/S (TTM) | 3.19 |
P/B | 2.25 |
EV/R | 0.46 |
EV/Ebitda | 2.58 |
PEG | NM |
Compugen (CGEN) share price today is $1.52
Yes, Indians can buy shares of Compugen (CGEN) on Vested. To buy Compugen from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Compugen (CGEN) via the Vested app. You can start investing in Compugen (CGEN) with a minimum investment of $1.
You can invest in shares of Compugen (CGEN) via Vested in three simple steps:
The 52-week high price of Compugen (CGEN) is $3.03. The 52-week low price of Compugen (CGEN) is $1.35.
The price-to-earnings (P/E) ratio of Compugen (CGEN) is 51
The price-to-book (P/B) ratio of Compugen (CGEN) is 2.25
The dividend yield of Compugen (CGEN) is 0.00%
The market capitalization of Compugen (CGEN) is $136.99M
The stock symbol (or ticker) of Compugen is CGEN